p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer

被引:153
作者
Fondevila, C
Metges, JP
Fuster, J
Grau, JJ
Palacín, A
Castells, A
Volant, A
Pera, M
机构
[1] Univ Barcelona, Sch Med, IDIBAPS,Hosp Clin, Inst Malalties Digest,Serv Gastrointestinal Surg, E-08036 Barcelona, Spain
[2] Ctr Hosp Univ Cavale Blanche & Morvan, Dept Pathol, Brest, France
[3] Ctr Hosp Univ Cavale Blanche & Morvan, Dept Med Oncol, Brest, France
[4] Univ Barcelona, Sch Med, IDIBAPS,Hosp Clin, Dept Med Oncol, E-08036 Barcelona, Spain
[5] Univ Barcelona, Sch Med, IDIBAPS,Hosp Clin, Dept Pathol, E-08036 Barcelona, Spain
[6] Univ Barcelona, Sch Med, IDIBAPS,Hosp Clin, Inst Malalties Digest,Serv Gastroenterol, E-08036 Barcelona, Spain
关键词
angiogenesis; gastric cancer; p53; VEGF; prognostic factors; microvessel density;
D O I
10.1038/sj.bjc.6601455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was undertaken to determine the value of tumour microvessel density (MVD) and the expression of p53 and vascular endothelial growth factor (VEGF) as prognostic markers in patients with gastric cancer operated on for cure. In all, 156 patients with curatively resected gastric cancer constituted the basis of this blinded retrospective evaluation. Patients were treated with either surgery alone (n=53) or surgery plus adjuvant chemotherapy (n=103). Tumour MVD, p53 expression, and VEGF expression were assayed using immunohistochemical techniques. After a mean follow-up of 43 months, 64 (41%) patients had died and 55 (35%) patients developed tumour recurrence. Positive correlations between MVD and both p53 (P=0.005) and VEGF (P=0.005) expression were observed. Both MVD greater than or equal to100 (P=0.05) and positive VEGF expression (P<0.02) were associated with shorter disease-free survival, and positive VEGF expression (P=0.01) was also associated with shorter overall survival. Multivariate analysis confirmed that, in addition to the pathological tumour stage, lymph node ratio, the extent of lymphadenectomy and perineural invasion, p53 expression, and VEGF expression were independently associated with both disease-free survival (P<0.0005 and 0.02, respectively) and overall survival (P<0.02 and 0.01, respectively). Finally, patients whose tumours did not show p53 expression had a survival benefit compared to those expressing p53 when treated with adjuvant chemotherapy (P=0.01).This investigation demonstrates that p53 expression and VEGF expression are independent prognostic factors for both disease-free survival and overall survival in patients with curatively resected gastric cancer, and that p53 status may also influence response to chemotherapy.
引用
收藏
页码:206 / 215
页数:10
相关论文
共 65 条
[1]   Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer [J].
Averbach, AM ;
Jacquet, P .
BRITISH JOURNAL OF SURGERY, 1996, 83 (06) :726-733
[2]   Relationship of p53 and vascular endothelial growth factor expression to clinicopathological factors in human scirrhous gastric cancer [J].
Baba, M ;
Konno, H ;
Maruo, Y ;
Tanaka, T ;
Kanai, T ;
Matsumoto, K ;
Matsuura, M ;
Nishino, N ;
Maruyama, K ;
Nakamura, S ;
Baba, S .
EUROPEAN SURGICAL RESEARCH, 1998, 30 (02) :130-137
[3]  
Boku N, 1998, CLIN CANCER RES, V4, P1469
[4]  
Cascinu S, 1998, CANCER-AM CANCER SOC, V83, P1917, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1917::AID-CNCR6>3.0.CO
[5]  
2-1
[6]   Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer [J].
Che, XM ;
Hokita, S ;
Natsugoe, S ;
Tanabe, G ;
Baba, M ;
Takao, S ;
Kuroshima, K ;
Aikou, T .
ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (07) :585-589
[7]   MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53 [J].
CHIN, KV ;
UEDA, K ;
PASTAN, I ;
GOTTESMAN, MM .
SCIENCE, 1992, 255 (5043) :459-462
[8]  
Díez M, 2000, ANTICANCER RES, V20, P3929
[9]   Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials [J].
Earle, CC ;
Maroun, JA .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (07) :1059-1064
[10]  
GABBERT HE, 1995, CANCER, V76, P720, DOI 10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO